Skip to content

Ketamine for depression: all studies

Page 94 of 178: studies 931 to 940 of 1,775, newest first. Back to the ketamine for depression overview

Research

Research trends and hotspots of ketamine from 2014 to 2023: a bibliometric analysis.

Frontiers in Neuroscience 2024 Yida Wang, Sile Chang, Dongxu Chen 2 citations

Despite this growing interest, there remains a lack of comprehensive and systematic bibliometric analyses of ketamine research. This study aimed to summarize the progress in ketamine research through bibliometric analysis, providing insights into the development and direction of the field. Publications related to ketamine were retrieved from the Web of Science Core Collection (WoSCC) database...

DOI: 10.3389/fnins.2024.1407301 (opens in new tab) Full text (opens in new tab) Analgesic Anesthesia Bibliometric analysis Ketamine therapy +4

Immediate and long-term electrophysiological biomarkers of antidepressant-like behavioral effects after subanesthetic ketamine and medial prefrontal cortex deep brain stimulation treatment.

Frontiers in Neuroscience 2024 Matthew Bergosh, Sasha Medvidovic, Nancy Zepeda et al. 6 citations

Both ketamine (KET) and medial prefrontal cortex (mPFC) deep brain stimulation (DBS) are emerging therapies for treatment-resistant depression, yet our understanding of their electrophysiological mechanisms and biomarkers is incomplete. This study investigates aperiodic and periodic spectral parameters, and the signal complexity measure sample entropy, within mPFC local field potentials (LFP)...

A scientometric analysis of research on the role of NMDA receptor in the treatment of depression.

Frontiers in Pharmacology 2024 Xulin Chen, Xian Wang, Caijuan Li et al. 7 citations

There have been numerous studies on NMDA receptors as therapeutic targets for depression. However, so far, there has been no comprehensive scientometric analysis of this field. Thus, we conducted a scientometric analysis with the aim of better elucidating the research hotspots and future trends in this field. Publications on NMDAR in Depression between 2004 and 2023 were retrieved from the Web...

DOI: 10.3389/fphar.2024.1394730 (opens in new tab) Full text (opens in new tab) Nmda receptor Bibliometrics Evidence synthesis Research trends +5

Ketamine in the effective management of chronic pain, depression, and posttraumatic stress disorder for Veterans: A meta-analysis and systematic review.

Frontiers in Psychiatry 2024 Jenny J W Liu, Natalie Ein, Julia Gervasio et al. 13 citations

Ketamine has emerged as a promising treatment alternative for the management of chronic pain. Despite encouraging findings in civilian populations, and favourable results from trials examining its efficacy in military populations, there is still a dearth of information pointing to optimal specifications related to ketamine administration for pain, depression, and posttraumatic stress disorder...

DOI: 10.3389/fpsyt.2024.1338581 (opens in new tab) Full text (opens in new tab) Mental health Veterans-military-servicemembers Mental-Health-PTSD-Depression-Trauma Ketamine-therapy-treatment +2

Effects of esketamine on depression-like behavior and dendritic spine plasticity in the prefrontal cortex neurons of spared nerve injury-induced depressed mice.

Brazilian Journal of Medical and Biological Research 2024 Bixin Huang, Xiaoling Li, Yuling Zheng et al. 4 citations

The present study utilized the spared nerve injury (SNI) to create a mouse model of depression to investigate the impact of esketamine on depressive-like behaviors, on the expression of PSD-95 and CRMP2 proteins, and on changes in neuronal dendritic spine plasticity in the prefrontal cortex (PFC). Depressive-like behavioral tests were performed 1 h after esketamine treatment, and the PFC...

Blood pressure changes during ketamine infusion for the treatment of depression.

General Hospital Psychiatry 2024 Mina Ansari, Brian Pittman, Daniel S Tylee et al. 6 citations

This study aimed to examine blood pressure changes during ketamine infusion for depression and exploring the factors associated with these changes. This study is a retrospective chart-review of patients with depression undergoing ketamine infusion at Yale Psychiatry Hospital during a 7-year period. Blood pressure (BP) was recorded every 10 min during the infusion. Surges in systolic and...

DOI: 10.1016/j.genhosppsych.2024.07.001 (opens in new tab) Full text (opens in new tab) Esketamine Cardiovascular changes Severe hypertension Cardiovascular safety +4

Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study.

Frontiers in Psychiatry 2024 Bruno Pedraz-Petrozzi, Moritz Spangemacher, Anton Deicher et al. 6 citations

Neuroinflammatory processes in depression are associated with treatment resistance to conventional antidepressants. Ketamine is an effective new therapeutic option for treatment-resistant depression (TRD). Its well-established immunomodulatory properties are hypothesized to mediate its antidepressant effect. In this context, higher levels of inflammation may predict a better treatment response....

Major challenges in youth psychopathology: treatment-resistant depression. A narrative review.

Frontiers in Psychiatry 2024 Giulia Menculini, Gianmarco Cinesi, Francesca Scopetta et al. 10 citations

Major depressive disorder (MDD) represents a major health issue in adolescents and young adults, leading to high levels of disability and profoundly impacting overall functioning. The clinical presentation of MDD in this vulnerable age group may slightly differ from what can be observed in adult populations, and psychopharmacological strategies do not always lead to optimal response. Resistance...

Predicting treatment response to ketamine in treatment-resistant depression using auditory mismatch negativity: Study protocol.

PLoS One 2024 Josh Martin, Fatemeh Gholamali Nezhad, Alice Rueda et al. 2 citations

Ketamine has recently attracted considerable attention for its rapid effects on patients with major depressive disorder, including treatment-resistant depression (TRD). Despite ketamine's promising results in treating depression, a significant number of patients do not respond to the treatment, and predicting who will benefit remains a challenge. Although its antidepressant effects are known to...

DOI: 10.1371/journal.pone.0308413 (opens in new tab) Full text (opens in new tab) Mental-health Depression-treatment Ketamine-therapy Biomarkers

Successful treatment for serious depression with suicidal risk in a heart transplant patient.

Revista Colombiana de psiquiatria 2024 María Del Mar Arango-Posada, Ana Isabel Prada-Escobar, Carolina Marín-Hernández et al.

Major depressive disorder is related to unfavourable outcomes in patients with severe comorbidities. In transplant patients, major depression is associated with worse clinical outcomes. We present the case of a 55-year-old man with a heart transplant due to heart failure of ischaemic origin. Six months after the transplant he developed depressed mood, anhedonia and suicidal ideation with a...